Abstract
It has been shown that docosahexaenoic acid (DHA) prevents nonalcoholic fatty liver disease (NAFLD) and insulin resistance (IR) caused by conjugated linoleic acid (CLA), a trans fatty acid (TFA). Here, we evaluated whether DHA will reverse existing CLA-induced NAFLD and IR in mice. DHA-specific effects on existing NAFLD involved significant (P < 0.005) lowering of hepatic weight and triacylglycerol content and expression of genes involved in fatty acid synthesis, enhancing expression of genes involved in fatty acid oxidation, and increasing serum adiponectin levels. Also, immunohistochemistry showed lower expression of hepatic CD163 (inflammation) and smooth muscle α-actin (fibrosis). Compared to the CLA diet, mice fed DHA and control diets had significantly (P < 0.05) lower serum insulin and ALT activity, but only DHA had lower (P = 0.05) expression of genes involved in fibrosis. DHA supplementation for 4 weeks reversed already existing hepatic steatosis, inflammation, and fibrosis caused by CLA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
